1. On May 15, 2017, Xiamen Weijia pharmaceutical was officially established with a registered capital of RMB 20 million.

2. In 2018, the core products of the factory, such as litonavir, lopinavir and praziquantel, passed the audit of many Indian Multinational companies, without major and major defects. The quality management system of the factory meets the management requirements of GMP.

3. At the beginning of 2019, it is planned to build Weijia Shaowu branch, with an actual investment of 120 mu, which is expected to be completed by the end of next year.